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ABSTRACT
Obesity has long been linked with prostate cancer progression, although the 
underlying mechanism is still largely unknown. Here, we report that adipocytes 
promote the enrichment of prostate cancer stem cells (CSCs) through a vicious cycle 
of autocrine amplification. In the presence of adipocytes, prostate cancer cells actively 
secrete the peptide hormone cholecystokinin (CCK), which not only stimulates prostate 
CSC self-renewal, but also induces cathepsin B (CTSB) production of the adipocytes. 
In return, CTSB facilitates further CCK secretion by the cancer cells. More importantly, 
inactivation of CCK receptor not only suppresses CTSB secretion by the adipocytes, but 
also synergizes the inhibitory effect of CTSB inhibitor on adipocyte-promoted prostate 
CSC self-renewal. In summary, we have uncovered a novel mechanism underlying the 
mutual interplay between adipocytes and prostate CSCs, which may help explaining 
the role of adipocytes in prostate cancer progression and provide opportunities for 
effective intervention.
INTRODUCTION
Prostate cancer is the second most common cause 
of solid tumours in men worldwide [1]. Despite recent 
advances in the detection of early prostate cancer, there 
remains no effective therapy for patients with metastatic 
disease [2]. The majority of patients with advanced 
disease will respond initially to androgen ablation therapy. 
However, 75-80% of them will go on to develop bone 
metastasis and once the tumor established in the bone, the 
disease is considered as incurable [3-5].
Tumor metastasis develops when cancer cells 
disseminate into the circulation, colonize secondary 
tissues and redevelop into bulk tumors [6]. Recent 
evidence supports the idea that tumor metastasis originates 
from a rare population of cancer cells known as cancer 
stem cells (CSCs). CSCs are characterized by their highly 
invasive characteristics and by their ability to self-renew 
and differentiate into heterogeneous lineages of cancer 
cells [7]. The unique plasticity of CSCs also allows them 
to undergo the phenotypic switch known as the epithelial-
to-mesenchymal transition (EMT) [8], which facilitates 
the mobilization and homing of tumor cells to target 
organs [9]. The stemness of CSCs is highly dependent on 
the presence of a stem cell niche. Recent studies suggested 
that CSCs are capable of creating their own niche by 
recruiting mesenchymal stem cells or macrophages, 
resulting in expansion of the CSC population within the 
tumor microenvironment [10, 11]. The same process 
is suggested to occur during the development of bone 
metastasis, whereby disseminated prostate and breast 
tumor cells with CSC properties have been found to 
occupy the hematopoietic stem cell niche and hijacking 
the signalling pathways within bone marrow [12-14]. 
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Therefore, identifying the key components of the CSC 
niche that support prostate cancer metastasis may offer 
opportunities for new treatment strategies.
Emerging data from recent studies support that 
adipocytes play a key role in prostate tumor metastasis. 
For example, obesity, which is associated with abnormal 
growth and functions of adipocytes, has been shown 
to correlate strongly with tumor metastasis in prostate 
cancer patients. Meanwhile, high-fat diet has also been 
consistently shown to promote the development of 
prostate tumor metastasis [15]. Furthermore, adipocytes 
isolated from periprostatic adipose tissues were found 
to induce invasiveness of prostate cancer cells [16]. 
Recently, adipocytes have also been reported to stimulate 
the growth and aggressiveness of prostate cancer cell 
through the production of a number of adipokines [17-20]. 
Considering that adipocyte lineage cells were found to 
stimulate follicular stem cell expansion [21], it is possible 
that adipocytes may promote prostate tumor metastasis by 
contributing to the formation of a CSC niche within the 
tumor microenvironment.
Here, we demonstrated the role of adipocytes in 
supporting self-renewal of prostate CSCs. We found 
that co-culturing of prostate cancer cells with adipocytes 
resulted in CSC enrichment, which was associated 
with upregulation of cholecystokinin (CCK), a peptide 
hormone regulating fat digestion and satiety. CCK not 
only functions as an autocrine factor to promote CSC self-
renewal, but also acts as a paracrine factor on adipocyte to 
stimulate the secretion of the cysteine protease cathepsin 
B (CTSB). Surprisingly, CCK secretion by the cancer 
cells was found to be induced by CTSB, suggesting that 
CCK and CTSB contribute to an autocrine/paracrine 
amplification loop that mediates the mutual interplay 
between prostate CSCs and adipocytes.
RESULTS
Adipocytes promote prostate CSC self-renewal
In order to understand the mutual interplay between 
adipocytes and prostate CSCs population, mouse prostate 
cancer cell line (TRAMP-C1) was allowed to grow in 
a non-adherent condition in the presence or absence 
of adipocytes (derived from the mouse 3T3-L1 pre-
adipocyte cell line). Co-culturing with fully differentiated 
adipocytes strongly induced the self-renewal ability of the 
TRAMP-C1 cells, as evidenced by the drastic induction 
of spheroid formation (1 vs 12) under co-culture 
conditions (Figure 1A&1B). Apart from increasing the 
number of prostaspheres formed, the size of individual 
prostaspheres was also significantly increased in the 
presence of adipocytes adipocytes (Figure 1B). Similarly, 
adipocytes also promoted spheroid formation of three 
other mouse prostate cancer cell lines TC1-T5, RM1 
and RM1-BM (Suppl. Figure 1). Meanwhile, adipocytes 
also significantly induced the formation of secondary 
prostaspheres (Figure 1C&1D), further confirming the 
effect of adipocytes on prostate CSC self-renewal ability. 
Consistently, mouse bone marrow derived adipocytes 
(OP9) and human SGBS adipocytes also promoted the 
prostatsphere formation of TRAMP-C1 and PC-3 cells to 
a similar extent respectively (Suppl. Figure 2 and data not 
shown), suggesting that the CSC-promoting effect may 
be common among adipocytes derived from different 
origins.
To validate our findings, western blotting and 
flow cytometry analysis of common CSC markers were 
performed. As shown in Figure 1E, protein expression 
of Notch1, CD49f, Sca-1 and Nanog in TRAMP-C1 
cells was significantly upregulated after co-culturing 
with adipocytes. Furthermore, the percentage of cells 
expressing the two putative CSC markers CD49f and 
Sca-1 was significantly upregulated after co-culturing 
with adipocytes (Figure 1F). These results confirm that 
adipocytes actively promote self-renewal of prostate 
CSCs, leading to subsequent expansion of CSC 
population, supporting the notion that adipose tissues 
may contribute to a metastatic niche necessary for the 
maintenance of prostate CSCs.
Adipocytes induce a CCK autocrine loop in 
prostate CSCs
To understand the underlying mechanism that 
drives the active self-renewal of prostate CSCs under 
the co-culture conditions, cDNA microarray analysis 
was performed to compare the gene expression profile 
of TRAMP-C1 cells that grow alone or in the presence 
of adipocytes. As expected, expression of a number of 
known stemness factors such as ALDH1A1, GFI-1 or 
ITGA2 were highly induced in TRAMP-C1 cells in the 
presence of adipocytes (Figure 2A and Suppl. Figure 
3). However, the gene that showed the highest level 
of induction was found to encode the protein CCK 
(Figure 2A and Suppl. Table 1), a peptide hormone 
expresses mainly by the mucosal epithelium in response 
to consumption of high-fat diet. Subsequent analysis 
with Real time- polymerase chain reaction (RT-PCR) 
and Enzyme-linked immunosorbent assay (ELISA) 
confirmed that both CCK mRNA and protein secretion 
were upregulated in prostate cancer cells in the presence 
of adipocytes (Figure 2B&2C and Suppl. Figure 4). 
Surprisingly, prostate cancer cell lines were found to 
actively expressing the CCK receptor CCKBR (Figure 
2D). Since activation of CCKBR has recently been 
shown to promote the stemness of colon cancer cells 
[22], it is possible that the induction of CCK expression 
by adipocytes may lead to the activation of an autocrine 
loop and as a result promote CSC self-renewal. Indeed, 
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while CCK mRNA was expressed at low level in both 
TRAMP-C1 and LNCaP cells, the corresponding bone 
metastatic sublines (i.e. TC1-T5 and C42B), which are 
enriched with CSC population (Suppl. Figure 5), were 
both found to express higher level of CCK transcript 
(Figure 2E). Meanwhile, treatment with human 
recombinant CCK not only induced the expression of 
CSC marker in TRAMP-C1 cells (Figure 2F), but also 
promotes the formation of prostasphere by the cells 
(Figure 2G), indicating the importance of CCK in 
regulating prostate CSC self-renewal. To confirm our 
findings, TRAMP-C1 cells were treated with a CCKBR 
specific inhibitor (i.e. YM022). As shown in Figure 2H, 
inhibition of CCKBR was found to suppress CSC marker 
expression in TRAMP-C1 cells. More importantly, 
CCKBR inhibition was found to suppress the promoting 
effect of adipocytes on spheroid formation of the cancer 
cells (Figure 2I), supporting that adipocytes stimulate 
prostate CSC self-renewal by facilitating the activation 
of the CCK/CCKBR autocrine loop.
CCK stimulates CTSB secretion of the 
adipocytes
Since CCK has been shown to regulate the function 
of adipocytes through activation of the CCKBR, we 
therefore speculate that by actively secreting CCK, 
prostate CSCs may also influence the co-cultured 
adipocytes, possibly in a way that favour their self-
renewal ability. Indeed, mass spectrometry analysis of 
the conditioned medium (CM) from adipocytes before 
and after co-cultured with prostate CSCs revealed that the 
cysteine protease CTSB, which plays an important role in 
prostate cancer progression [23], was among the proteins 
induced in adipocytes under the co-culture condition 
(Figure 3A). Subsequent analysis of the CM with ELISA 
Figure 1. Adipocytes promote prostate CSC self-renewal A. Adipocytes stimulate formation of prostaspheres. TRAMP-C1 
cells were seeded in ultra-low attachment plates in the presence or absence of 3T3-L1-derived adipocytes. After 7 days, prostaspheres 
formed were counted under the microscope. B. Representative images of the prostaspheres. C&D. Primary TRAMP-C1 prostasphere were 
dissociated and were allowed to grow as secondary prostaspheres in the presence of adipocytes. E&F. Expression of CSC markers by 
TRAMP-C1 cells or the prostatsphere formed under the co-culture conditions were examined by western blotting (Notch 1, CD49f, Sca-1 
and Nanog) and flow cytometry (CD49f and Sca-1) respectively. The results are presented as the mean ± SD from triplicate experiments. 
(p values: * < 0.05, ** < 0.005, *** < 0.0005).
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further confirmed that CTSB secretion was upregulated 
in adipocytes that have been co-cultured with prostate 
CSCs (Figure 3B), although the mRNA level of CTSB 
was not induced under the same condition (Figure 3C). 
Similarly, CTSB secretion, but not the mRNA level (data 
not shown), was induced in adipocytes that were treated 
with recombinant CCK (Figure 3D). However, the effect 
of the recombinant CCK was abolished in the presence of 
YM022 (Figure 3E), confirming that CCK induced CTSB 
through activation of the CCKBR.
CCK and CTSB contributes to an autocrine/
paracrine amplification loop
One of the key functions of cathepsin protein 
family is the regulation of peptide hormone release and 
activation [24]. For example, CSTB has been shown to 
promote the liberation of thorexine at the apical membrane 
[25]. Meanwhile, cathepsin L1 was also found to induce 
the processing of pro-CCK, leading to an increase in the 
secretion of the active CCK [26]. Although CTSB has not 
Figure 2. Adipocytes induce the cholecystokinin autocrine loop in prostate CSCs A. Genes upregulated in TRAMP-C1 
prostatsphere after co-culturing with adipocytes (grown in an insert) were identified with cDNA microarray analysis and the top 50 genes 
were displayed as a heat map. B. Upregulation of CCK mRNA in TRAMP-C1 prostaspheres was validated with RT-PCR. C. ELISA was 
performed to confirm the induction of CCK production in TRAMP-C1 cells after co-culturing with adipocytes. D. CCKBR expression 
was analysed in mouse (TRAMP-C1, TC1-T5) and human prostate cancer cell lines (LNCaP and C42B) using western blotting. E. CCK is 
upregulated in metastatic prostate cancer cells. mRNA level of CCK in TRAMP-C1, LNCaP and their corresponding metastatic sublines 
(TC1-T5 and C42B) were analysed by RT-PCR. F. Effect of CCK treatment on CSC marker expression in prostate cancer cells. TRAMP-C1 
cells were treated with recombinant CCK for 48 hours and the expression of CD49f was examined using western blotting. G. CCK 
promotes prostasphere formation by TRAMP-C1 cells. TRAMP-C1 cells were seeded in an ultra-low attachment plate in the presence or 
absence of human recombinant CCK. After 7 days, prostaspheres formed were counted under the microscope. H. Inhibition of CCKBR 
downregulated CSC marker expression (CD49f) in TRAMP-C1 cells. Cells treated with either the vehicle or CCKBR inhibitor (YM022 ) 
(10 and 25 µM) were lysed and subjected to western blot analysis against the indicated proteins. I. Inhibition of CCKBR abolishes the effect 
of adipocytes on prostasphere formation. TRAMP-C1 cells co-cultured with adipocytes were treated with different doses of the YM022 
(5 and 10 µM) and the prostaspheres formed under each condition were counted under microscope. All experiments were repeated at least 
three times, and the results are presented as the mean ± SD. (p values: * < 0.05, ** < 0.005, *** < 0.0005).
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been reported to regulate CCK secretion, we found that 
treatment of TRAMP-C1 cells with recombinant CTSB 
resulted in significant upregulation of CCK level in the 
conditioned medium (Figure 4A) without affecting CCK 
mRNA levels (data not shown). Meanwhile, inhibition 
of CTSB significantly suppressed CCK production by 
the cancer cells, further supporting that CTSB regulates 
CCK secretion (Figure 4B). Since CCK is also capable of 
inducing CTSB production of adipocytes, we anticipated 
that this autocrine/paracrine amplification loop may play 
a key role in sustaining the adipocyte-promoted prostate 
CSC self-renewal. Consistent with our hypothesis, the 
promoting effect of adipocytes on prostasphere formation 
was significantly suppressed in the presence of CTSB 
inhibitor (CA-074ME) (Figure 4C). Meanwhile, CA-
074ME was found to significantly enhance the effect 
of YM022 against prostasphere formation (Figure 4D). 
These results clearly indicate the critical role of this 
novel autocrine/paracrine loop in mediating the effect of 
adipocytes on prostate CSC self-renewal Summarized in 
Figure 4E.
DISCUSSION
The frequent invasion of local tumor into 
periprostatic adipose tissues and the metastasis of 
advanced tumors into the adipocyte-rich bone marrow 
clearly suggest the importance of adipose tissues during 
prostate cancer progression [27, 28]. What is not yet clear 
is how prostate cancer cells interact with the adipocytes 
to support their eventual expansion into metastatic tumor. 
Here, we report for the first time that adipocytes actively 
interplay with prostate CSCs through a novel autocrine/
paracrine amplification loop, leading to rapid enrichment 
of the CSC population.
Figure 3. CCK stimulates CTSB secretion by the adipocytes A. Protein secretion profiles of 3T3-L1-derived adipocytes before or 
after being co-cultured with TRAMP-C1 cells was determined by mass spectrometry. Proteins upregulated under the co-culture condition 
were listed in Table A. B&C. ELISA and RT-PCR were performed to validate the induction of CTSB expression in adipocytes after co-
culture with TRAMP-C1 cells. (D&E) Secretion of CTSB in adipocytes is regulated by CCK. D. 3T3-L1-derived adipocytes were treated 
with CCK recombinant protein (0.2µg/ml) for 4 hours and the level of CTSB in the conditioned medium was analysed by ELISA. E. 
Addition of YM022 (1 and 5 µM) completely abolished the effects of CCK on CTSB induction. Each experiment was repeated at least three 
times, and the results are presented as the mean ± SD. (p values: * < 0.05, ** < 0.005).
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Similar to normal stem cells, the stemness of 
prostate CSCs is highly dependent on the presence of a 
stem cell niche [29]. The stromal cells within the primary 
prostate tumor appear to play a key role in promoting the 
tumorigenicity of the prostate cancer cells, as evidenced by 
the ability of cancer associated fibroblasts in transforming 
normal prostate epithelial cells [30]. Similarly, our 
finding that adipocytes actively stimulate prostate CSC 
self-renewal support the proposal that adipose tissues 
may contribute to a metastatic niche necessary for the 
maintenance of prostate CSCs. Since obesity is associated 
with adipocyte dysfunction and abnormal adiposity, the 
resulting enrichment of the metastatic niches (i.e. the 
periprostatic adipose tissues and bone marrow fat) may in 
turn contribute to the frequent tumor metastasis and poor 
prognosis observed in obese prostate cancer patients [15].
The significant upregulation of CCK mRNA in 
prostate cancer cells upon co-cultured with adipocytes 
suggests that CCK is playing an important role in 
mediating the effect of adipocytes on CSC self-renewal. 
Expression of CCK was believed to be restricted to the 
enteroendocrine cells and to specialized neurons within 
the brain [31, 32]. It is therefore surprising that CCK and 
its receptor were both found to be expressed by prostate 
cancer cells. Our study therefore represents the first to 
discover the autocrine function of CCK in the maintenance 
of prostate CSCs. Exactly how CCK promotes the 
stemness of prostate CSCs is still unclear, although the 
Figure 4. CCK and CTSB contribute to an autocrine/paracrine amplification loop A. CTSB regulates the secretion of CCK 
by prostate cancer cells. TC1-T5 cells were treated with recombinant CTSB protein (0.2µg/ml) for 4 hours and the level of CCK in 
the conditioned medium was determined by ELISA. B. Inhibition of CTSB with CTSB inhibitor CA-074ME (10µM) suppresses CCK 
secretion in TC1-T5 cells. C. CTSB inhibition suppressed the promoting effect of adipocytes on prostatsphere formation in a dose dependent 
manner. TRAMP-C1 cells co-cultured with 3T3-L1-derived adipocytes were treated with different dosage of CA-074ME (5, 10 and 20µM). 
Prostaspheres were counted and imaged at day 7. D. CTSB inactivation sensitizes prostate CSCs to YM022 treatment. TRAMP-C1 cells co-
cultured with 3T3-L1-derived adipocytes were treated with the YM022 alone or in combination with CA-074ME. After 7 days, prostaspheres 
formed were counted and imaged under the microscope. E. Summary of the proposed role of adipocytes on prostate CSC maintenance. Each 
experiment was repeated at least three times, and the results are presented as the mean ± SD. (p values: * < 0.05, ** < 0.005, *** < 0.0005).
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binding and activation of CCKBR by gastrin, a hormone 
peptide structurally related to CCK, was found to regulate 
the proliferation of normal and malignant colon stem cells 
through suppression of both BMP-2 and Id4 expression 
[22]. Since CCK also binds to and activates CCKBR, it is 
possible that CCK may act through the same downstream 
signalling pathway.
Dietary fat is the major risk factor not only for 
obesity, but also for prostate cancer progression [33, 
34]. Intake of dietary fat is known to induce a rapid 
upregulation of CCK expression by the enteroendocrine 
cells within the intestine [35]. Therefore, long term high-fat 
diet consumption is expected to result in chronic elevation 
of serum CCK level. Indeed, in a recent study, mice that 
consumed a high-fat diet were found to have ten fold higher 
of serum CCK level when compared to the control group 
[36]. In pancreatic cancer, CCK expression was also found 
to associate with larger tumors and a higher incidence of 
metastasis [36, 37]. Considering that prostate cancer cells 
also express CCKBR and respond to CCK stimulation, 
the effects of high-fat diet on prostate tumor progression 
reported previously [38] may well be a consequence of 
CCK elevation. Therefore, exposing the cancer cells to a 
high lipid content (i.e. high-fat diet or co-culturing with 
adipocytes) may promote the CCK-autocrine loop and 
further driven the expansion of prostate CSCs.
It is worth noting that CCK not only regulates fat 
and protein digestion, but also controls the level of satiety. 
In an animal study, systemic administration of CCK 
was found to induce anorexia [39]. Meanwhile, serum 
CCK level was found to be significantly higher in older 
individuals [40], and is suggested to contribute to aging-
associated anorexia. Since we found that CCK expression 
is highly upregulated in bone metastatic prostate cancer 
cells, it is possible that CCK secreted by cancer cells may 
contribute to the anorexia commonly found in advanced 
stage cancer patients, although further examination of 
serum CCK level in prostate cancer patients is needed to 
confirm this hypothesis.
Our findings suggest that the secretion of CCK 
by prostate CSCs may also play roles in modulating the 
function of adipocytes, possibly in a way that further 
facilitates CSC expansion. One of the key pieces of 
evidence is the stimulation of CTSB secretion by the 
adipocytes, which in turn further promotes the secretion 
of CCK by the cancer cells. Our discovery of this 
seemingly paracrine/autocrine amplification loop may 
help in explaining the mutual interplay between prostate 
cancer cells and adipocytes. More importantly, despite 
the presence of adipocytes, disruption of this loop by 
means of inactivating either CCK receptor or CTSB 
can significantly inhibit prostate CSC expansion, clearly 
demonstrating the therapeutic potential of this paracrine/
autocrine amplification loop for targeting CSC population.
In summary, we have identified a novel mechanism 
that mediates the interaction between adipocytes and 
prostate cancer cells, which may offer opportunities for the 
development of new treatment against metastatic prostate 
cancer.
MATERIALS AND METHODS
Spheroid formation assay
The spheroid formation assay was modified from a 
previously reported protocol [41, 42]. Briefly, cells were 
harvested and counted using a Scepter™ Automated Cell 
Counter (Millipore, Billerica, MA, USA). Four hundred 
cells were added to each well of a 24-well ultra-low 
attachment plates (Sigma-Aldrich, St. Louis, MO, USA). 
Adipocytes differentiated from the 3T3-L1 cells were 
then added into a cell culture insert (0.4 μM) (Millipore) 
placed inside the well. Cells were grown in DMEM/F12 
(Invitrogen, Carlsbad, CA, USA), supplemented with 
10 μg/mL insulin (Sigma-Aldrich), B27 (Invitrogen), 
80 ng/mL EGF (Sigma-Aldrich) and 40 ng/mL basic 
FGF (Invitrogen). The number of spheroids formed was 
counted at Day 7 or at the end of the treatment. Each 
experiment was performed in triplicate and was repeated 
at least 3 times, with each data point represents the mean 
and SD. Statistical difference was determined by Student’s 
t test and was considered as significant if p < 0.05.
Western blot
Experimental procedures have been described 
in our previous study [43]. Firstly, cell pellets were 
collected and lysed with lysis buffer (Cell Signalling 
Technology, Danvers, MA, USA) containing 100 µM 
phenylmethylsulfonyl fluoride (PMSF; Sigma-Aldrich). 
The cell lysates were quantified using the Pierce™ 
BCAProtein Assay Kit (Thermo Fisher Scientific, 
Rockford, IL, USA) before loading onto a SDS-
polyacrylamide gel. The resolved proteins were then 
transferred onto a PVDF membrane (Millipore) which 
was then blocked with 10% skim milk in TBST-T buffer 
at room temperature. After the blocking, the membrane 
was probed with the indicated antibody for 1 hour at 
room temperature prior to being washed with TBS-T. The 
membrane was then incubated with the corresponding 
secondary antibody for another hour at room temperature. 
After washing with TBS-T, the membrane was incubated 
with Immobilon Western Chemiluminescent HRP 
Substrate (Millipore), and the signals were visualized 
and quantified using a Bio-Rad ChemiDoc™ XRS Gel 
Documentation System.
Flow cytometry analysis
Experimental procedures have been described by the 
manufacturer. Briefly, cells were collected, washed twice 
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with phosphate-buffered saline (PBS) and subsequently 
resuspended in 50 μl of fluorescence-activated cell 
sorting (FACS) buffer (0.02% sodium azide and 2% 
FBS in PBS) before incubating with the fluorescent dye-
conjugated antibodies at 4°C in the dark for 30 minutes. 
After incubation, the cells were washed twice with PBS 
and resuspended in 200 μl of FACS buffer, and the flow 
cytometry analysis was performed using the BD™ LSR 
II. The results were then analysed using the KALUZA 
software.
Microarray analysis
TRAMP-C1 cells that were grown alone or co-
cultured with adipocyte were lysed for RNA extraction 
with the RNeasy Mini Kit (Qiagen, Germantown, MD, 
USA) following with the manufacturer’s instructions. 
The resulting RNA was used for the generation of labeled 
cDNA based on the protocol described earlier [44]. cDNA 
was probed against the Mouse GE 44K v2 Microarray 
G2519F-026655 (Agilent Technologies, Santa Clara, CA, 
USA) according to standard procedures, and the signals 
were read by the Agilent scanner and analyzed with 
Genespring software.
Real time- polymerase chain reaction  
(RT-PCR)
Total RNA was isolated using the RNeasy Mini 
Kit (Qiagen) and 2 μg of the resulting RNA was used 
to synthesize cDNA using the SuperScript® III First-
Strand Synthesis Systems (Invitrogen) as described by the 
manufacturer’s instruction manual. RT-PCR was carried 
out with the ViiA™ 7 Real-Time PCR System (Applied 
Biosystems, Foster City, CA, USA). Sense and anti-sense 
primers specific for the genes of interest are listed in 
Suppl. Table 2. The transcript level of ribosomal protein 
L32 (RPL32) was used as an internal control. Note that, 
standard curve was used to quantify the CCK transcript 
level in human prostate cancer cell lines and transcript 
level was normalised as number of copies.
Liquid chromatography–Mass spectrometry 
(LC-MS/MS)
Concentrated conditioned media (collected from 
fresh adipocyte or adipocyte co-cultured with TRAMP-C1 
prostasphere) containing 19 ug of protein as quantitated by 
Pierce™ BCA Protein Assay Kit was separated on a SDS-
PAGE to 8 mm and visualised by colloidal coomassie. 
Protein gel slices (1 mm) were excised using a clean gel 
cutter (The Gel Company San Francisco, CA,USA) and 
were transferred to 96-well U bottom plate containing 
a solution of 50% acetonitrile: 25mM NH4HCO3 for 
destaining. Samples were reduced with 20mM DTT 
followed by alkylation with 50mM IAA. The samples 
were equilibrated to pH-8 with 50 mM NH4HCO3 and 
subsequently dehydrated with 100% acetonitrile. Proteins 
were extracted with 60% acetonitrile, 1% formic acid, 
dried in a speed-vac and resuspended in 10 μL of 5% v/v 
formic acid for LC-MS/MS.
Peptides were analyzed using a 1200 Series 
nano HPLC and Chip-Cube Q-TOF 6510 (Agilent 
Technologies). HPLC loading pump was set to 3% B, flow 
rate of 4uL/min while analytical pump was set to 10%B 
and flow rate of 0.3uL/min. Mass spectrometry data were 
analysed using Spectrum Mill (Agilent, B.04.00.127) 
search engine. Extracted data were searched against 
Swiss-Prot Release 2012-01-25 database containing 
534,242 sequence entries, with mouse species, fixed 
cysteine carbamidomethylation and variable methionine 
oxidation selected. Precursor and product mass tolerance 
was set to +/- 20ppm and ±=/- 50ppm respectively. Protein 
identification cut-offs were set to protein score > 11, 
peptide score >10 and scored peak intensity > 60% [45].
ELISA
To quantify CCK and CTSB secretion, conditioned 
medium was collected and analysed using either the CCK 
Enzyme Immunoassay (EIA) Kit (Sigma-Aldrich) or the 
CTSB Mouse ELISA Kit (Abcam, Cambridge, MA, USA) 
following with manufacturer’s instructions. Signals were 
detected using a LUMIstar OPTIMA Luminescence 
Microplate Reader. All results were then normalised as 
fold changes relative to the control.
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protein 4 (FABP4), Fetal bovine serum (FBS), Fibroblast 
growth factor (FGF), Fluorescence-activated cell sorting 
(FACS), Liquid chromatography–Mass spectrometry 
(LC-MS/MS), Minimum Essential Medium (MEM), 
Phenylmethylsulfonyl fluoride (PMSF), Phosphate-
buffered saline (PBS), Phycoerythrin (PE), Real time- 
polymerase chain reaction (RT-PCR), Penicillin-
streptomycin (P/S), Ribosomal protein L32 (RPL32) 
andTris Buffered Saline with Tween® 20 (TBST-T).
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